0001209191-23-005554.txt : 20230130
0001209191-23-005554.hdr.sgml : 20230130
20230130184057
ACCESSION NUMBER: 0001209191-23-005554
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230126
FILED AS OF DATE: 20230130
DATE AS OF CHANGE: 20230130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Donegan Michael C
CENTRAL INDEX KEY: 0001627810
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-00100
FILM NUMBER: 23569575
MAIL ADDRESS:
STREET 1: 6800 BROKEN SOUND PARKWAY NW
STREET 2: THIRD FLOOR
CITY: BOCA RATON
STATE: FL
ZIP: 33487-3507
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TherapeuticsMD, Inc.
CENTRAL INDEX KEY: 0000025743
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870233535
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 951 YAMATO ROAD, SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
BUSINESS PHONE: 561-961-1900
MAIL ADDRESS:
STREET 1: 951 YAMATO ROAD, SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
FORMER COMPANY:
FORMER CONFORMED NAME: AMHN, Inc.
DATE OF NAME CHANGE: 20090930
FORMER COMPANY:
FORMER CONFORMED NAME: CROFF ENTERPRISES INC
DATE OF NAME CHANGE: 19970915
FORMER COMPANY:
FORMER CONFORMED NAME: CROFF OIL CO
DATE OF NAME CHANGE: 19920703
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-26
0
0000025743
TherapeuticsMD, Inc.
TXMD
0001627810
Donegan Michael C
951 YAMATO ROAD
SUITE 220
BOCA RATON
FL
33431
0
1
0
0
Prin. Fin. and Acctg. Officer
Common Stock
2023-01-26
4
M
0
2400
0.00
A
10010
D
Common Stock
2023-01-26
4
M
0
2400
0.00
A
12410
D
Common Stock
2023-01-26
4
M
0
1140
0.00
A
13550
D
Common Stock
2023-01-26
4
S
0
1648
5.0796
D
11902
D
Common Stock
2023-01-27
4
S
0
49
5.09
D
11853
D
Performance Stock Units
0.00
2023-01-26
4
M
0
2400
0.00
D
Common Stock
2400
0
D
Performance Stock Units
0.00
2023-01-26
4
M
0
2400
0.00
D
Common Stock
2400
0
D
Performance Stock Units
0.00
2023-01-26
4
M
0
1140
0.00
D
Common Stock
1140
0
D
Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs).
The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.01 through $5.17, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".
/s/ Michael C. Donegan
2023-01-30